Guardant Health SEC Filings

Guardant Health director Tariq Musa reported the vesting and conversion of 250 restricted stock units into common shares on 08/15/2025 at no cash price, increasing his direct common stock holdings to 7,574 shares. The filing shows he continues to hold 4,747 restricted stock units after the transaction. The RSUs were part of a grant dated March 6, 2023 that vests over four years with 25% vesting on the one-year anniversary (March 15, 2023) and the remainder vesting monthly over the following three years. The Form 4 was signed by an attorney-in-fact on 08/18/2025.

Myrtle S. Potter, a director of Guardant Health, Inc. (GH), reported a grant vesting on 08/15/2025 that resulted in the acquisition of 69 shares of common stock at no cash price. After the reported transaction Potter beneficially owns 18,265 shares. The filing lists the underlying award as Restricted Stock Units that vested in part earlier: 25% vested on October 15, 2022, with the remaining 75% scheduled to vest in substantially equal monthly installments over the following three years. The Form 4 was signed by an attorney-in-fact on 08/18/2025.

Guardant Health (GH) Form 4: Director Steve E. Krognes reported the automatic conversion of 154 restricted stock units (RSUs) into an equal number of common shares on 07/31/2025 (transaction code “M”). No shares were sold. The RSUs stem from an August 9 2022 grant that vested 25 % on 06/30/2023; the remaining 75 % continue to vest in equal monthly installments through mid-2026.

Following the conversion, Krognes now holds 17,973 shares directly and retains 1,698 un-settled RSUs. The transaction was priced at $0, indicating a standard equity award settlement rather than an open-market purchase. Ownership structure remains direct, and no 10b5-1 plan was indicated.

Guardant Health, Inc. (GH) – SEC Form 4 filing dated 07/07/2025

Director Meghan V. Joyce reported the acquisition of 66 common shares on 07/04/2025 through the settlement of previously granted Restricted Stock Units (RSUs). The RSUs carried a $0 conversion price, so no cash changed hands. Following the transaction, Joyce’s direct beneficial ownership increases to 11,216 common shares.

The underlying RSU award vested 25 % on 08/04/2022, with the remaining 75 % vesting in equal monthly installments over three years (through 08/04/2025). No derivative securities were disposed of, and the transaction was coded “M” (acquisition from the company without open-market purchase).

The filing is routine, involves a small share count relative to Guardant Health’s outstanding shares, and contains no financial performance information or strategic disclosures.

Guardant Health, Inc. (GH) – Form 4 filing (07/02/2025)

Chief Information Officer Kumud Kalia reported routine equity transactions tied to the vesting of previously granted restricted stock units (RSUs) on July 1 2025:

• 2,691 common shares were issued upon the automatic conversion of RSUs (Transaction Code M) at a zero exercise price.
• 1,365 shares were simultaneously surrendered to the company to cover statutory tax-withholding obligations (Transaction Code F) at a market price of $50.71.
• After the net share settlement, Kalia’s direct ownership increased by 1,326 shares to a total of 20,500 common shares.

The derivative table shows that the executive still holds 8,035 unvested RSUs from a November 7 2022 grant and 5,419 unvested RSUs from a December 13 2023 grant, each vesting quarterly over their remaining terms. No open-market sales or purchases were reported beyond the withheld shares, indicating that the insider retained all newly vested stock net of taxes.

This filing reflects standard equity-compensation activity; it does not disclose any new option grants, cash transactions, or information that would materially alter Guardant Health’s financial outlook. The scale of the net acquisition is immaterial relative to the company’s total shares outstanding, but it modestly increases insider alignment.